Tearsheet
EDIT Home Investment Highlights Valuation, Metrics & Events Price Chart Why The Stock Moved Return vs. Risk About EDIT Interactive Breakdown Better Bets vs. EDIT Latest Trefis Analyses Trade Ideas More From Trefis Peer Comparisons FDIC Bank Data FDA Approved Drugs Data Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Insider Activity Trade Sentinel Industry Resource Links External Quote Links

Editas Medicine (EDIT)

Market Price (3/15/2026): $2.46 | Market Cap: $239.5 Mil
Sector: Health Care | Industry: Biotechnology

Editas Medicine (EDIT)

Market Price (3/15/2026): $2.46
Market Cap: $239.5 Mil
Sector: Health Care
Industry: Biotechnology

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0 Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -54%		 Weak multi-year price returns
2Y Excs Rtn is -106%, 3Y Excs Rtn is -142%		 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -99 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -245%
1 Megatrend and thematic drivers
Megatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, and Targeted Therapies. 		Meaningful short interest
Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 12%		 Weak revenue growth
Rev Chg QQuarterly Revenue Change % is -19%
2   Significant share based compensation
SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 25%
3   Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -408%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -409%
4   Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -72%
0 Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -54%
1 Megatrend and thematic drivers
Megatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, and Targeted Therapies.
2 Weak multi-year price returns
2Y Excs Rtn is -106%, 3Y Excs Rtn is -142%
3 Meaningful short interest
Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 12%
4 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -99 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -245%
5 Weak revenue growth
Rev Chg QQuarterly Revenue Change % is -19%
6 Significant share based compensation
SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 25%
7 Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -408%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -409%
8 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -72%

Valuation, Metrics & Events

Price Chart

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Editas Medicine (EDIT) stock has remained largely at the same level since 11/30/2025 because of the following key factors:

1. Improved Financial Stability and Extended Cash Runway Offset by Restructuring Costs.

Editas Medicine significantly narrowed its net loss for the fourth quarter of 2025 to $5.6 million, or $0.06 per share, a substantial improvement from a net loss of $45.4 million, or $0.55 per share, in the same period of 2024. For the full year 2025, the company's net loss decreased by 32% to $160.1 million. This financial improvement was primarily driven by reduced research and development (R&D) and general and administrative (G&A) expenses due to the discontinuation of the reni-cel program. The company also reported a robust cash position of $146.6 million as of December 31, 2025, providing a projected cash runway into the third quarter of 2027. However, these positive financial developments were tempered by increased restructuring and impairment charges, which rose to $60.7 million in 2025 from $12.2 million in 2024, associated with winding down prior programs and workforce reductions.

2. Early-Stage Clinical Progress for Lead Candidate EDIT-401 with Future Milestones.

The company's lead in vivo gene editing candidate, EDIT-401, targeting heterozygous familial hypercholesterolemia (HeFH), demonstrated promising preclinical results, achieving over 90% mean LDL-C reduction in non-human primate studies. Editas Medicine remains on track to submit an Investigational New Drug (IND)/Clinical Trial Application (CTA) for EDIT-401 by mid-2026, initiate its first-in-human clinical trial later in 2026, and anticipates early human proof-of-concept data by year-end 2026. While these advancements are positive and provide a clear development timeline, the candidate is still in early clinical stages, meaning significant clinical and regulatory hurdles remain, contributing to a cautious investor stance.

Show more

Stock Movement Drivers

Fundamental Drivers

The 1.2% change in EDIT stock from 11/30/2025 to 3/14/2026 was primarily driven by a 25.2% change in the company's P/S Multiple.
(LTM values as of)113020253142026Change
Stock Price ($)2.412.441.2%
Change Contribution By: 
Total Revenues ($ Mil)4641-12.6%
P/S Multiple4.75.925.2%
Shares Outstanding (Mil)9097-7.5%
Cumulative Contribution1.2%

LTM = Last Twelve Months as of date shown

Market Drivers

11/30/2025 to 3/14/2026
ReturnCorrelation
EDIT1.2% 
Market (SPY)-3.1%36.1%
Sector (XLV)-5.0%35.7%

Fundamental Drivers

The -5.1% change in EDIT stock from 8/31/2025 to 3/14/2026 was primarily driven by a -13.3% change in the company's Shares Outstanding (Mil).
(LTM values as of)83120253142026Change
Stock Price ($)2.572.44-5.1%
Change Contribution By: 
Total Revenues ($ Mil)39414.2%
P/S Multiple5.65.95.1%
Shares Outstanding (Mil)8497-13.3%
Cumulative Contribution-5.1%

LTM = Last Twelve Months as of date shown

Market Drivers

8/31/2025 to 3/14/2026
ReturnCorrelation
EDIT-5.1% 
Market (SPY)3.0%30.2%
Sector (XLV)9.5%28.0%

Fundamental Drivers

The 27.1% change in EDIT stock from 2/28/2025 to 3/14/2026 was primarily driven by a 128.6% change in the company's P/S Multiple.
(LTM values as of)22820253142026Change
Stock Price ($)1.922.4427.1%
Change Contribution By: 
Total Revenues ($ Mil)6241-34.4%
P/S Multiple2.65.9128.6%
Shares Outstanding (Mil)8297-15.3%
Cumulative Contribution27.1%

LTM = Last Twelve Months as of date shown

Market Drivers

2/28/2025 to 3/14/2026
ReturnCorrelation
EDIT27.1% 
Market (SPY)12.4%40.6%
Sector (XLV)1.9%38.2%

Fundamental Drivers

The -73.0% change in EDIT stock from 2/28/2023 to 3/14/2026 was primarily driven by a -81.4% change in the company's P/S Multiple.
(LTM values as of)22820233142026Change
Stock Price ($)9.042.44-73.0%
Change Contribution By: 
Total Revenues ($ Mil)2041105.6%
P/S Multiple31.65.9-81.4%
Shares Outstanding (Mil)6997-29.3%
Cumulative Contribution-73.0%

LTM = Last Twelve Months as of date shown

Market Drivers

2/28/2023 to 3/14/2026
ReturnCorrelation
EDIT-73.0% 
Market (SPY)73.4%30.1%
Sector (XLV)23.3%27.4%

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
EDIT Return-62%-67%14%-87%61%30%-96%
Peers Return10%-39%9%-36%7%13%-44%
S&P 500 Return27%-19%24%23%16%-1%80%

Monthly Win Rates [3]
EDIT Win Rate17%33%50%17%67%67% 
Peers Win Rate37%42%47%40%57%53% 
S&P 500 Win Rate75%42%67%75%67%33% 

Max Drawdowns [4]
EDIT Max Drawdown-62%-69%-30%-88%-23%-19% 
Peers Max Drawdown-25%-50%-28%-40%-34%-8% 
S&P 500 Max Drawdown-1%-25%-1%-2%-15%-2% 

[1] Cumulative total returns since the beginning of 2021
[2] Peers: CRSP, NTLA, BEAM, VRTX, CRBU. See EDIT Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 3/13/2026 (YTD)

How Low Can It Go

Unique KeyEventEDITS&P 500
2022 Inflation Shock2022 Inflation Shock  
2022 Inflation Shock% Loss% Loss-93.1%-25.4%
2022 Inflation Shock% Gain to Breakeven% Gain to Breakeven1349.3%34.1%
2022 Inflation ShockTime to BreakevenTime to BreakevenNot Fully Recovered days464 days
2020 Covid Pandemic2020 Covid Pandemic  
2020 Covid Pandemic% Loss% Loss-54.6%-33.9%
2020 Covid Pandemic% Gain to Breakeven% Gain to Breakeven120.3%51.3%
2020 Covid PandemicTime to BreakevenTime to Breakeven98 days148 days
2018 Correction2018 Correction  
2018 Correction% Loss% Loss-58.7%-19.8%
2018 Correction% Gain to Breakeven% Gain to Breakeven142.3%24.7%
2018 CorrectionTime to BreakevenTime to Breakeven719 days120 days

Compare to CRSP, NTLA, BEAM, VRTX, CRBU

In The Past

Editas Medicine's stock fell -93.1% during the 2022 Inflation Shock from a high on 1/8/2021. A -93.1% loss requires a 1349.3% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Editas Medicine (EDIT)

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has an early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

AI Analysis | Feedback

Moderna for genetic diseases, but using CRISPR gene-editing technology.

An early-stage Intel for the human genome, building foundational CRISPR tools to repair DNA.

The Adobe of human DNA, developing powerful CRISPR tools to precisely edit and correct disease-causing genes.

AI Analysis | Feedback

  • EDIT-101: A gene-editing therapy in clinical trials for Leber Congenital Amaurosis 10, an inherited childhood blindness.
  • EDIT-102: A gene-editing therapy in development for Usher Syndrome 2A and autosomal dominant retinitis pigmentosa, both affecting vision and sometimes hearing.
  • EDIT-301: A gene-editing therapy designed to treat sickle cell disease and transfusion-dependent beta-thalassemia.
  • Gene-edited Natural Killer (NK) cell medicines: Therapies under development that modify NK cells to treat solid tumor cancers.
  • Alpha-beta T cell therapies: Gene-edited T cell therapies being developed for various cancers.
  • Gamma delta T cell therapies: Gene-edited T cell therapies in development for treating different types of cancer.
  • Neurological disease therapy (Early Discovery): A therapy in early discovery stages aimed at treating a specific neurological disease.

AI Analysis | Feedback

Editas Medicine (EDIT) is a clinical-stage genome editing company focused on developing genomic medicines. As such, it does not currently sell approved products directly to individuals (patients). Instead, its primary "customers" are other companies with which it forms strategic alliances and research collaborations for the development and potential commercialization of its therapies. These collaborations often involve upfront payments, milestone payments, and future royalties, which represent Editas Medicine's revenue streams from these partners.

Based on the provided information, Editas Medicine's major corporate partners (customers) include:

  • Juno Therapeutics, Inc.
  • Allergan Pharmaceuticals International Limited
  • Asklepios BioPharmaceutical, Inc. (AskBio)

AI Analysis | Feedback

null

AI Analysis | Feedback

null

AI Analysis | Feedback

null

AI Analysis | Feedback

null

AI Analysis | Feedback

null

AI Analysis | Feedback

null

AI Analysis | Feedback

null

Better Bets vs. Editas Medicine (EDIT)

Latest Trefis Analyses

TitleDate
0DASHBOARDS 
1Editas Medicine Earnings Notes12/16/2025
2Would You Still Hold Editas Medicine Stock If It Fell Another 30%?10/17/2025
3Editas Medicine (EDIT) Stock: 35% of days in last 3 months had 1% or greater fluctuation04/30/2025
4Editas Medicine Market Price04/23/2025
5Day 5 of Gains Streak for Editas Medicine Stock with 171% Return (vs. 152% YTD) [2/20/2025]02/20/2025
6Day 1 of Loss Streak for Editas Medicine Stock with -1.2% Return (vs. -66% YTD) [10/17/2024]10/17/2024
7Editas Medicine vs. S&P500 Correlation10/03/2024
8Editas Medicine Price Volatility09/24/2024
9Day 8 of Gains Streak for Editas Medicine Stock with 10% Return (vs. 1.1% YTD) [7/12/2023]07/12/2023
10Day 6 of Loss Streak for Editas Medicine Stock with -30% Return (vs. -10% YTD) [6/22/2023]06/22/2023
11ARTICLES 
12The Sell Off In Gene Editing Stocks Continues. Time To Buy?02/08/2022
13Bluebird, Editas: Gene Editing Stocks Had A Tough Year. Will 2022 Be Better?12/22/2021
14Is The Selling In Editas Stock Overdone?09/30/2021
15Will The Rally In Editas Stock Continue After A 20% Rise In A Month?08/10/2021
16Editas, Intellia: After Big Sell Off, Is it Time To Buy Gene Editing Stocks?03/05/2021
Title
0DASHBOARDS
1Editas Medicine Earnings Notes
2Would You Still Hold Editas Medicine Stock If It Fell Another 30%?
3Editas Medicine (EDIT) Stock: 35% of days in last 3 months had 1% or greater fluctuation
4Editas Medicine Market Price
5Day 5 of Gains Streak for Editas Medicine Stock with 171% Return (vs. 152% YTD) [2/20/2025]
6Day 1 of Loss Streak for Editas Medicine Stock with -1.2% Return (vs. -66% YTD) [10/17/2024]
7Editas Medicine vs. S&P500 Correlation
8Editas Medicine Price Volatility
9Day 8 of Gains Streak for Editas Medicine Stock with 10% Return (vs. 1.1% YTD) [7/12/2023]
10Day 6 of Loss Streak for Editas Medicine Stock with -30% Return (vs. -10% YTD) [6/22/2023]
11ARTICLES
12The Sell Off In Gene Editing Stocks Continues. Time To Buy?
13Bluebird, Editas: Gene Editing Stocks Had A Tough Year. Will 2022 Be Better?
14Is The Selling In Editas Stock Overdone?
15Will The Rally In Editas Stock Continue After A 20% Rise In A Month?
16Editas, Intellia: After Big Sell Off, Is it Time To Buy Gene Editing Stocks?

Trade Ideas

Select ideas related to EDIT.

Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
QDEL_2282026_Insider_Buying_45D_2Buy_200K02282026QDELQuidelOrthoInsiderInsider Buys 45DStrong Insider Buying
Companies with multiple insider buys in the last 45 days		0.0%0.0%0.0%
CHE_2272026_Dip_Buyer_FCFYield02272026CHEChemedDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin		0.0%0.0%0.0%
LLY_2272026_Monopoly_xInd_xCD_Getting_Cheaper02272026LLYEli LillyMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		0.0%0.0%0.0%
HAE_2202026_Dip_Buyer_FCFYield02202026HAEHaemoneticsDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin		3.5%3.5%0.0%
IQV_2132026_Dip_Buyer_ValueBuy02132026IQVIQVIADip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		7.1%7.1%-3.0%
EDIT_3312021_Insider_Buying_45D_2Buy_200K03312021EDITEditas MedicineInsiderInsider Buys 45DStrong Insider Buying
Companies with multiple insider buys in the last 45 days		1.2%-54.7%-66.5%

Recent Active Movers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons

Peers to compare with:

Financials

EDITCRSPNTLABEAMVRTXCRBUMedian
NameEditas M.CRISPR T.Intellia.Beam The.Vertex P.Caribou . 
Mkt Price2.4448.7512.7625.16469.341.8818.96
Mkt Cap0.24.61.52.6119.00.22.0
Rev LTM4106814012,001954
Op Inc LTM-99-665-441-3844,554-147-265
FCF LTM-166-371-396-3603,194-128-263
FCF 3Y Avg-174-263-386-3001,832-123-218
CFO LTM-165-345-395-3453,631-126-255
CFO 3Y Avg-169-249-379-2812,225-116-209

Growth & Margins

EDITCRSPNTLABEAMVRTXCRBUMedian
NameEditas M.CRISPR T.Intellia.Beam The.Vertex P.Caribou . 
Rev Chg LTM25.4%-100.0%16.9%120.0%8.9%-19.0%12.9%
Rev Chg 3Y Avg87.7%28,190.6%15.4%185.6%10.4%28.8%58.2%
Rev Chg Q-19.2%-100.0%78.8%279.5%9.5%8.6%9.1%
QoQ Delta Rev Chg LTM-12.6%-100.0%17.6%150.9%2.4%1.9%2.1%
Op Mgn LTM-245.2%--651.7%-274.6%37.9%-1,577.4%-274.6%
Op Mgn 3Y Avg-400.4%--998.4%-325.2%24.7%-1,110.8%-400.4%
QoQ Delta Op Mgn LTM12.9%-180.5%562.6%38.7%127.0%127.0%
CFO/Rev LTM-407.8%--583.3%-247.0%30.3%-1,351.7%-407.8%
CFO/Rev 3Y Avg-409.3%--757.5%-277.7%20.5%-904.5%-409.3%
FCF/Rev LTM-409.3%--585.0%-257.7%26.6%-1,374.2%-409.3%
FCF/Rev 3Y Avg-420.9%--774.2%-289.0%17.0%-946.9%-420.9%

Valuation

EDITCRSPNTLABEAMVRTXCRBUMedian
NameEditas M.CRISPR T.Intellia.Beam The.Vertex P.Caribou . 
Mkt Cap0.24.61.52.6119.00.22.0
P/S5.9-21.918.59.918.918.5
P/EBIT-1.5-7.0-3.4-6.725.6-1.2-2.4
P/E-1.5-8.0-3.6-32.430.1-1.1-2.5
P/CFO-1.4-13.5-3.7-7.532.8-1.4-2.6
Total Yield-67.4%-12.5%-27.9%-3.1%3.3%-89.6%-20.2%
Dividend Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%
FCF Yield 3Y Avg-102.8%-5.7%-27.5%-12.8%1.7%-66.9%-20.1%
D/E0.10.00.10.10.00.10.1
Net D/E-0.5-0.4-0.2-0.4-0.0-0.7-0.4

Returns

EDITCRSPNTLABEAMVRTXCRBUMedian
NameEditas M.CRISPR T.Intellia.Beam The.Vertex P.Caribou . 
1M Rtn45.2%-0.4%9.8%-6.6%0.9%23.7%5.4%
3M Rtn-3.6%-14.0%41.5%-8.0%3.8%5.0%0.1%
6M Rtn-9.3%-13.3%11.7%22.1%19.0%4.4%8.1%
12M Rtn67.1%15.7%39.6%3.8%-7.0%86.1%27.7%
3Y Rtn-71.1%8.5%-68.8%-28.3%59.5%-63.6%-45.9%
1M Excs Rtn40.2%3.3%8.7%-0.8%4.1%20.6%6.4%
3M Excs Rtn-4.5%-13.7%37.8%-6.6%7.2%0.6%-2.0%
6M Excs Rtn-12.8%-15.6%8.9%13.9%15.3%-4.4%2.2%
12M Excs Rtn40.6%-8.9%11.6%-29.3%-26.3%56.3%1.4%
3Y Excs Rtn-142.0%-68.0%-138.0%-102.4%-5.2%-137.7%-120.1%

Financials

Segment Financials

Revenue by Segment
$ Mil20252024202320222021
Developing and commercializing genome editing technology7820269121
Total7820269121


Price Behavior

Price Behavior
Market Price$2.44 
Market Cap ($ Bil)0.2 
First Trading Date02/03/2016 
Distance from 52W High-41.2% 
   50 Days200 Days
DMA Price$2.06$2.55
DMA Trendupdown
Distance from DMA18.6%-4.3%
 3M1YR
Volatility91.2%99.0%
Downside Capture222.50223.12
Upside Capture242.63238.83
Correlation (SPY)34.7%37.8%
EDIT Betas & Captures as of 2/28/2026

 1M2M3M6M1Y3Y
Beta3.572.492.612.092.101.98
Up Beta4.565.875.151.581.971.83
Down Beta4.491.371.472.771.771.73
Up Capture416%240%229%161%539%572%
Bmk +ve Days9203170142431
Stock +ve Days10182455111325
Down Capture211%170%242%190%156%113%
Bmk -ve Days12213054109320
Stock -ve Days10213465132409

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
Annualized
Return		Annualized
Volatility		Sharpe
Ratio		Correlation
with EDIT
EDIT63.2%99.5%0.93-
Sector ETF (XLV)5.0%17.5%0.1238.0%
Equity (SPY)19.6%18.9%0.8138.3%
Gold (GLD)71.9%26.3%2.0513.3%
Commodities (DBC)19.3%17.3%0.8910.9%
Real Estate (VNQ)6.2%16.3%0.1934.0%
Bitcoin (BTCUSD)-15.3%44.2%-0.2535.6%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
Annualized
Return		Annualized
Volatility		Sharpe
Ratio		Correlation
with EDIT
EDIT-42.9%93.4%-0.20-
Sector ETF (XLV)7.5%14.5%0.3329.8%
Equity (SPY)13.1%17.0%0.6137.6%
Gold (GLD)24.1%17.3%1.148.4%
Commodities (DBC)11.2%19.0%0.475.0%
Real Estate (VNQ)4.8%18.8%0.1632.8%
Bitcoin (BTCUSD)6.3%56.7%0.3325.5%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
Annualized
Return		Annualized
Volatility		Sharpe
Ratio		Correlation
with EDIT
EDIT-23.5%84.2%0.05-
Sector ETF (XLV)10.1%16.5%0.5033.1%
Equity (SPY)14.5%17.9%0.7037.3%
Gold (GLD)14.4%15.6%0.775.2%
Commodities (DBC)8.6%17.6%0.409.7%
Real Estate (VNQ)5.6%20.7%0.2326.6%
Bitcoin (BTCUSD)67.4%66.8%1.0717.8%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date2272026
Short Interest: Shares Quantity11.9 Mil
Short Interest: % Change Since 21520261.2%
Average Daily Volume1.4 Mil
Days-to-Cover Short Interest8.2 days
Basic Shares Quantity97.3 Mil
Short % of Basic Shares12.2%

Returns Analyses

Earnings Returns History

Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
3/9/202616.0%  
11/10/20252.0%5.3%5.3%
8/12/202534.5%14.8%18.3%
5/12/2025-2.6%-3.2%31.8%
1/13/2025-7.9%-3.2%-6.3%
10/22/2024-12.5%-13.3%-34.0%
8/7/2024-12.2%-14.7%-25.4%
5/8/2024-11.4%0.0%-4.4%
...
SUMMARY STATS   
# Positive141110
# Negative91112
Median Positive9.7%9.2%21.1%
Median Negative-5.8%-5.4%-17.4%
Max Positive34.5%45.1%58.3%
Max Negative-12.5%-15.9%-34.0%

SEC Filings

Expand for More
Report DateFiling DateFiling
12/31/202503/09/202610-K
09/30/202511/10/202510-Q
06/30/202508/12/202510-Q
03/31/202505/12/202510-Q
12/31/202403/05/202510-K
09/30/202411/04/202410-Q
06/30/202408/07/202410-Q
03/31/202405/08/202410-Q
12/31/202302/28/202410-K
09/30/202311/03/202310-Q
06/30/202308/02/202310-Q
03/31/202305/05/202310-Q
12/31/202202/22/202310-K
09/30/202211/02/202210-Q
06/30/202208/03/202210-Q
03/31/202205/04/202210-Q

Insider Activity

Expand for More
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value		Value of
Held Shares		Form
1Burkly, LindaEVP, CHIEF SCIENTIFIC OFFICERDirectSell120420252.157131,535148,084Form
2O'Neill, Gilmore NeilCEODirectSell120420252.155,60312,064579,371Form
3Parison, AmySVP, Chief Financial OfficerDirectSell120420252.1546199334,252Form
4Burkly, LindaEVP, CHIEF SCIENTIFIC OFFICERDirectSell90420252.607101,843180,403Form
5Parison, AmySVP, Chief Financial OfficerDirectSell90420252.604581,18942,496Form

Industry Resources

External Quote Links


Prefer one of these to Trefis? Tell us why.